ADARx delivered clean IPO demand as Oura and Accelevation offered liquidity

ADARx Pharmaceuticals supplied the week ended September 27 with its cleanest IPO handoff. The RNA medicines developer increased its deal by 20%, priced at the top of the range, raised $446.3 million and closed its first session 13.8% above issue. That performance stood apart from the next two large transactions: Oura and Accelevation launched deals worth $2.1 billion and $660 million at their respective midpoints, but most of the stock in each is coming from existing holders.

The distinction matters after a week in which final terms and first trades again rewarded financing that puts cash onto the issuer’s balance sheet. ADARx offered investors a capital-intensive clinical story, then paired it with an all-primary raise and a strategic private placement. Oura and Accelevation brought stronger current revenue, but their proposed IPOs ask the market to provide substantial owner liquidity.

ADARx converted clinical risk into financing strength

ADARx sold 26.25 million shares at $17, up from the 21.875 million shares contemplated in its September 21 prospectus. The company’s pricing release put gross IPO proceeds at $446.3 million. AbbVie also agreed to buy shares at the IPO price in a concurrent private placement, subject to a $100 million cap, taking expected aggregate gross proceeds from the two transactions to $535.2 million.

The bookbuild and aftermarket both confirmed demand. Shares opened at $22.10, 30% above issue, and closed at $19.35, a 13.8% first-day gain, according to Reuters’ debut report. J.P. Morgan and Morgan Stanley led the book with TD Cowen, UBS and LifeSci Capital.

The financing still carries biotech’s familiar binary risks. ADARx recorded a $48.4 million net loss in the first half of 2026, up from $33.6 million a year earlier. Its prospectus directs proceeds toward clinical development, including Phase 1 work, other research and working capital. IPOGrid reads the successful upsizing as a vote for the company’s pipeline and balance-sheet runway, not as a public-market verdict on clinical efficacy. The useful signal is that investors funded the issuer at the top of range and then bid the stock higher.

Oura’s scale arrives with limited new corporate cash

Oura launched the week’s largest prospective IPO: 50 million shares at $40 to $44, or $2.1 billion at the midpoint. The amended prospectus shows that Oura is selling 13.5 million shares while existing holders are selling 36.5 million. The entire 7.5 million-share underwriters’ option also comes from selling stockholders. Eli Lilly indicated interest in as much as $100 million of stock and Dragoneer-affiliated funds in as much as $300 million, although indications are not binding orders.

The company’s operating momentum is substantial. Revenue reached $1.21 billion in the nine months through June, while paid members doubled to 5 million. Membership revenue rose 121% to $240.5 million and carried an 89% gross margin; hardware still represented roughly 80% of revenue. At $42, the basic equity value would be about $13.5 billion.

The use of proceeds changes how we would frame that valuation test. Oura estimates $532.6 million of net primary proceeds at the midpoint, then expects to use about $526.4 million for tax withholding tied to restricted stock units vesting in connection with the IPO. Pro forma cash rises only from $371.8 million to $377.9 million under the filing’s assumptions. Forerunner-affiliated funds are offering roughly 28.7 million shares, effectively their full disclosed position.

Oura has earned attention as a fast-growing consumer health platform with a valuable subscription layer. The reviewer’s concern is that new investors are being asked to support a premium valuation while most of the transaction supplies holder liquidity and the primary proceeds largely settle an IPO-triggered tax obligation. The offer can still work, especially with $400 million of indicated interest, but the clearing price will say more about appetite for scarce growth than about Oura’s need for expansion capital.

Accelevation brings the same test to AI infrastructure

Accelevation set 30 million shares at $20 to $24, valuing the data-center equipment supplier at about $4.9 billion at the midpoint. Its September 22 amendment divides the base offer into 8.6 million primary shares and 21.4 million secondary shares. Reuters reported a potential $720 million raise at the top of the range and a valuation of as much as $5.37 billion.

Accelevation sits directly in the data-center power and white-space buildout, and its $447.8 million of reported revenue gives investors a current earnings base to evaluate. The filing also shows $647.8 million of debt at June 30 and says issuer proceeds will repay borrowings. Yet 71% of the base deal is secondary. Our interpretation is that the IPO combines useful deleveraging with a much larger monetization by existing owners. A ten-bank syndicate led by Morgan Stanley, J.P. Morgan and Goldman Sachs gives the transaction reach; pricing will show whether the AI-infrastructure label is enough to support both purposes.

The calendar rewarded capital formation

Orion180’s final prospectus arrived during the week after the insurer had already priced 20 million shares at $12, below its $15 to $17 range. That filing closed the documentation loop but did not alter the prior week’s demand signal.

ADARx did alter it. The company increased supply, held the top of range and finished above issue while raising money for the business. Oura and Accelevation now face a more demanding comparison. Their operations have scale and their themes have scarcity value, but the composition of each offer puts owner liquidity at the center of the bookbuild. This week’s evidence says investors will pay for risk when the financing case is direct. The next test is how much they will pay when the seller is already inside.